TransCelerate BioPharma Introduces New Subsidiary BioCelerate to Increase Efficiencies in Preclinical Research

PHILADELPHIA--()--TransCelerate BioPharma, Inc. announced today that it is launching BioCelerate, a new subsidiary that aims to improve efficiencies in preclinical research. The six initial biopharmaceutical companies committed to launching BioCelerate include Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, Novo Nordisk and Shionogi & Co., Ltd. Each of these organizations are also Member Companies of TransCelerate BioPharma, a condition for participation in BioCelerate, and will lead the first initiative, Toxicology Data Sharing, which will enable access to a broader cross-company set of toxicology data.

"TransCelerate's commitment to collaboration has laid the foundation for the creation of BioCelerate. It is because of TransCelerate's successful track record in the clinical development space that a subset of its members have decided to leverage that infrastructure, governance model and methodologies for preclinical research. BioCelerate, like TransCelerate, will focus on pragmatic and tangible solutions to common challenges with the end goal of improving drug development efficiency and bringing new medicines to patients faster. The organization will seek to actively collaborate with multiple stakeholders to enhance the resources dedicated to solving these issues and will also ensure visibility of projects to regulatory agencies," said Dalvir Gill, Ph.D. CEO, TransCelerate BioPharma, Inc.

"Building upon the collaborative framework that TransCelerate has proven successful, BioCelerate will leverage the collective knowledge available within Member Companies to tackle areas of common challenge in the preclinical research space," said Francis Cuss, MB BCHIR, FRCP, Chief Scientific Officer, Bristol-Myers Squibb.

"In fact, BioCelerate's first initiative will focus on target-related toxicity in preclinical studies to enhance the data landscape in this stage of research within each Member Company and, ultimately, improve and accelerate drug development in the industry," Francis went on to say.

The mission of the Toxicology Data Sharing Initiative was in part motivated by the objectives charted by the Food and Drug Administration (FDA) to modernize toxicology to enhance product safety in the organization's 2011 Strategic Plan for Regulatory Science, as well as other ventures that aim to improve pace and effectiveness of drug development. The knowledge gathered through the BioCelerate Toxicology Data Sharing Initiative will help with effective translation of nonclinical findings and attempt to close critical gaps that exist in understanding the relationship between patient response and preclinical toxicology findings.

About BioCelerate

BioCelerate will explore areas in preclinical research that have unmet needs and could benefit from a collaborative approach.Initiatives will be approved by a governing council made up of participating BioCelerate Member Companies. Additional details on these initiatives will be released in 2016. BioCelerate is a separate legal subsidiary of TransCelerate BioPharma with separate funding and support. The organization will be led by TransCelerate CEO, Dalvir Gill. To participate in BioCelerate, you must be a Member Company of TransCelerate BioPharma, Inc. To learn more, visit

About TransCelerate BioPharma Inc.

TransCelerate BioPharma Inc. is a non-profit organization dedicated to improving the health of people around the world by accelerating and enhancing the research and development (R&D) of innovative new therapies. The organizations' mission is to collaborate across the global biopharmaceutical R&D community to identify, prioritize, design and facilitate implementation of solutions designed to drive the efficient, effective and high quality delivery of new medicines. TransCelerate evolved from conversations at various forums for executive R&D leadership to discuss current issues facing the industry, and examine solutions for addressing common challenges. The founding member companies are AbbVie, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, Johnson & Johnson, Pfizer, the Roche Group, and Sanofi. Additional members that have joined since the inception of TransCelerate include Allergan, Inc., Amgen, Astellas Pharma Inc., EMD Serono, Inc. (a subsidiary of Merck KGaA, Darmstadt, Germany), Medgenics, Inc., Merck & Co., Inc., Novo Nordisk, Shionogi & Co., Ltd. and UCB.

Membership in TransCelerate is open to pharmaceutical and biotechnology companies with Research & Development operations. Executive offices are located in Philadelphia, PA. For more information, please visit

Follow us on Twitter:

Reach us on LinkedIn:



Bliss Integrated Communication
Vicky Aguiar, 212-584-5470
[email protected]


Suggested Articles

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Independent site management organization Panthera Biopartners has kick-started its first clinical trial in the U.K.

WIRB-Copernicus Group’s clinical services division bought out trial consultancy firm Waife & Associates as it looks to boost its management services.